NR4A1 and breast cancer: In the overviews from the Early Breast Cancer Trialist Collaborative Group (EBCTCG) for hormone receptor-positive breast cancer, it was shown that 5 years of adjuvant tamoxifen therapy reduces the risk of breast cancer recurrence by approximately 40% [4].